TY - JOUR
T1 - Pathological findings in central nervous system demyelination associated with infliximab
AU - Kalinowska-Lyszczarz, Alicja
AU - Fereidan-Esfahani, Mahboobeh
AU - Guo, Yong
AU - Lucchinetti, Claudia F.
AU - Tobin, W. Oliver
N1 - Funding Information:
Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS. Demyelination central nervous system multiple sclerosis tumor necrosis factor (TNF) alpha inhibitors infliximab neuropathology rheumatoid arthritis Novartis https://doi.org/10.13039/100004336 CFTY720DUS37T National Institute of Neurological Disorders and Stroke https://doi.org/10.13039/100000065 R01 NS 49577-6 edited-state corrected-proof typesetter ts1 The authors acknowledge Patricia Ziemer for expert technical assistance with pathology. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from NIH R01 NS 49577-6 (C.F.L.) and Novartis CFTY720DUS37T (C.F.L.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Informed Consent Written informed consent was obtained from the patient according to the Declaration of Helsinki. ORCID iD W Oliver Tobin https://orcid.org/0000-0002-8141-2394
Publisher Copyright:
© The Author(s), 2019.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.
AB - Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.
KW - Demyelination
KW - central nervous system
KW - infliximab
KW - multiple sclerosis
KW - neuropathology
KW - rheumatoid arthritis
KW - tumor necrosis factor (TNF) alpha inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85077379821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077379821&partnerID=8YFLogxK
U2 - 10.1177/1352458519894710
DO - 10.1177/1352458519894710
M3 - Article
C2 - 31845616
AN - SCOPUS:85077379821
SN - 1352-4585
VL - 26
SP - 1124
EP - 1129
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 9
ER -